In vivo SPECT imaging of vesicular acetylcholine transporter using [123I]-IBVM in early Alzheimer's disease

NeuroImage

Volumn 40, Issue 1, 2008, Pages 280-288

  Mazere J ^a,b   Prunier, C ^c   Barret, O ^a,b   Guyot, M ^a   Hommet, C ^c,d   Guilloteau, D ^c,d   Dartigues, J F ^e,f   Auriacombe, S ^e,f   Fabrigoule, C ^b,f   Allard, M ^a,b,g  

^a HÔPITAL PELLEGRIN   (France)

^b UMR 5287   (France)

^c CHU BRETONNEAU   (France)

^d UNIVERSITÉ DE TOURS   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f INSERM   (France)

^g PSL RESEARCH UNIVERSITY   (France)

Author keywords

123I iodobenzovesamicol; Alzheimer's disease; Single Photon Emission Computed Tomography; Vesicular acethylcholine transporter

Indexed keywords

CONTRAST MEDIUM; IODINE 123; IODOBENZOVESAMICO I 123; UNCLASSIFIED DRUG; VESICULAR ACETYLCHOLINE TRANSPORTER;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN REGION; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; IMAGE ANALYSIS; IN VIVO STUDY; LINEAR REGRESSION ANALYSIS; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAHIPPOCAMPAL AMYGDALOID COMPLEX; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL PARAMETERS; STATISTICAL PARAMETRIC MAPPING; STUDENT T TEST;

AGED; ALZHEIMER DISEASE; ATROPHY; BRAIN; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; ISOTOPE LABELING; MALE; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VESICULAR ACETYLCHOLINE TRANSPORT PROTEINS;

EID: 39049094581     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2007.11.028     Document Type: Article

References (41)

1. Almkvist O., Jelic V., Amberla K., Hellstrom-Lindahl E., Meurling L., and Nordberg A. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. Dement. Geriatr. Cogn. Disord. 12 1 (2001) 22-32
2. Amieva H., Rouch-Leroyer I., Fabrigoule C., and Dartigues J.F. Deterioration of controlled processes in the preclinical phase of dementia: a confirmatory analysis. Dement. Geriatr. Cogn. Disord. 11 1 (2000) 46-52
3. Braak H., and Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol. Aging 18 Suppl. 4 (1997) S85-S88
4. Braak H., and Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J. Neural Transm., Suppl. 53 (1998) 127-140
5. Carcaillon L., Peres K., Pere J.J., Helmer C., Orgogozo J.M., and Dartigues J.F. Fast cognitive decline at the time of dementia diagnosis: a major prognostic factor for survival in the community. Dement. Geriatr. Cogn. Disord. 23 6 (2007) 439-445
6. Cullen K.M., and Halliday G.M. Neurofibrillary degeneration and cell loss in the nucleus basalis in comparison to cortical Alzheimer pathology. Neurobiol. Aging 19 4 (1998) 297-306
7. DeKosky S.T., Ikonomovic M.D., Styren S.D., Beckett L., Wisniewski S., Bennett D.A., Cochran E.J., Kordower J.H., and Mufson E.J. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol. 51 2 (2002) 145-155
8. Delacourte A., David J.P., Sergeant N., Buee L., Wattez A., Vermersch P., Ghozali F., Fallet-Bianco C., Pasquier F., Lebert F., et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 52 6 (1999) 1158-1165
9. Fabrigoule C., Rouch I., Taberly A., Letenneur L., Commenges D., Mazaux J.M., Orgogozo J.M., and Dartigues J.F. Cognitive process in preclinical phase of dementia. Brain 121 Pt 1 (1998) 135-141
10. Farlow M.R., and Cummings J.L. Effective pharmacologic management of Alzheimer's disease. Am. J. Med. 120 5 (2007) 388-397
11. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive test of patients for the clinician. J. Psychiatr. Res. 12 (1975) 189-198
12. Frisoni G.B., Pievani M., Testa C., Sabattoli F., Bresciani L., Bonetti M., Beltramello A., Hayashi K.M., Toga A.W., and Thompson P.M. The topography of grey matter involvement in early and late onset Alzheimer's disease. Brain 130 Pt 3 (2007) 720-730
13. Geula C., Greenberg B.D., and Mesulam M.M. Cholinesterase activity in the plaques, tangles and angiopathy of Alzheimer's disease does not emanate from amyloid. Brain Res. 644 2 (1994) 327-330
14. Gilmor M.L., Erickson J.D., Varoqui H., Hersh L.B., Bennett D.A., Cochran E.J., Mufson E.J., and Levey A.I. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J. Comp. Neurol. 411 4 (1999) 693-704
15. Goekoop R., Scheltens P., Barkhof F., and Rombouts S.A. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation-A pharmacological fMRI study. Brain 129 Pt 1 (2006) 141-157
16. Gsell W., Strein I., and Riederer P. The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared. J. Neural Transm., Suppl. 47 (1996) 73-101
17. Hanyu H., Asano T., Sakurai H., Tanaka Y., Takasaki M., and Abe K. MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia. AJNR Am. J. Neuroradiol. 23 1 (2002) 27-32
18. Hanyu H., Tanaka Y., Sakurai H., Takasaki M., and Abe K. Atrophy of the substantia innominata on magnetic resonance imaging and response to donepezil treatment in Alzheimer's disease. Neurosci. Lett. 319 1 (2002) 33-36
19. Herholz K., Bauer B., Wienhard K., Kracht L., Mielke R., Lenz M.O., Strotmann T., and Heiss W.D. In-vivo measurements of regional acetylcholine esterase activity in degenerative dementia: comparison with blood flow and glucose metabolism. J. Neural Transm. 107 12 (2000) 1457-1468
20. Herholz K., Weisenbach S., Zundorf G., Lenz O., Schroder H., Bauer B., Kalbe E., and Heiss W.D. In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease. NeuroImage 21 1 (2004) 136-143
21. Herholz K., Weisenbach S., Kalbe E., Diederich N.J., and Heiss W.D. Cerebral acetylcholine esterase activity in mild cognitive impairment. NeuroReport 16 13 (2005) 1431-1434
22. Jung Y.W., Van Dort M.E., Gildersleeve D.L., and Wieland D.M. A radiotracer for mapping cholinergic neurons of the brain. J. Med. Chem. 33 8 (1990) 2065-2068
23. Jung Y.W., Frey K.A., Mulholland G.K., del Rosario R., Sherman P.S., Raffel D.M., Van Dort M.E., Kuhl D.E., Gildersleeve D.L., and Wieland D.M. Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol. J. Med. Chem. 39 17 (1996) 3331-3342
24. Kadir A., Darreh-Shori T., Almkvist O., Wall A., Langstrom B., and Nordberg A. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET. Psychopharmacology (Berl) 191 4 (2007) 1005-1014
25. Kuhl D.E., Koeppe R.A., Fessler J.A., Minoshima S., Ackermann R.J., Carey J.E., Gildersleeve D.L., Frey K.A., and Wieland D.M. In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM. J. Nucl. Med. 35 3 (1994) 405-410
26. Kuhl D.E., Koeppe R.A., Fessler J.A., Minoshima S., Ackermann R.J., Carey J.E., Frey K.A., and Wieland D.M. In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM. J. Nucl. Med. 35 (1994) 405-410
27. Kuhl D.E., Minoshima S., Fessler J.A., Frey K.A., Foster N.L., Ficaro E.P., Wieland D.M., and Koeppe R.A. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann. Neurol. 40 3 (1996) 399-410
28. Kuhl D.E., Koeppe R., Minoshima S., Snyder S., Ficaro E., Foster N., Frey K., and Kilbourn M. In vivo mapping of cerebral acethylcholinesterase activity in aging and Alzheimer's disease. Neurology 10, 52 4 (1999) 691-699
29. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 7 (1984) 939-944
30. Mesulam M.M., Mufson E.J., Levey A.I., and Wainer B.H. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J. Comp. Neurol. 214 2 (1983) 170-197
31. Perry E.K., and Perry R.H. Neurochemistry of consciousness: cholinergic pathologies in the human brain. Prog. Brain Res. 145 (2004) 287-299
32. Perry E.K., Haroutunian V., Davis K.L., Levy R., Lantos P., Eagger S., Honavar M., Dean A., Griffiths M., McKeith I.G., et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. NeuroReport 5 7 (1994) 747-749
33. Perry E., Walker M., Grace J., and Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness?. Trends Neurosci. 22 6 (1999) 273-280
34. Potkin S.G., Anand R., Fleming K., Alva G., Keator D., Carreon D., Messina J., Wu J.C., Hartman R., and Fallon J.H. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int. J. Neuropsychopharmacol. 4 3 (2001) 223-230
35. Rombouts S.A., Barkhof F., Veltman D.J., Machielsen W.C., Witter M.P., Bierlaagh M.A., Lazeron R.H., Valk J., and Scheltens P. Functional MR imaging in Alzheimer's disease during memory encoding. AJNR Am. J. Neuroradiol. 21 10 (2000) 1869-1875
36. Selden N.R., Gitelman D.R., Salamon-Murayama N., Parrish T.B., and Mesulam M.M. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 121 Pt 12 (1998) 2249-2257
37. Talairach J., and Tournoux P. Co-planar Stereotactic Atlas of the Human Brain. Thieme, Stuttgart, NY. (1988)
38. Teipel S.J., Flatz W.H., Heinsen H., Bokde A.L., Schoenberg S.O., Stockel S., Dietrich O., Reiser M.F., Moller H.J., and Hampel H. Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain 128 Pt 11 (2005) 2626-2644
39. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., and Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. NeuroImage 15 1 (2002) 273-289
40. Van Dort M.E., Jung Y.W., Gildersleeve D.L., Hagen C.A., Kuhl D.E., and Wieland D.M. Synthesis of the 123I- and 125I-labeled cholinergic nerve marker (-)-5-iodobenzovesamicol. Nucl. Med. Biol. 20 8 (1993) 929-937
41. Vellas B., Cunha L., Gertz H.J., De Deyn P.P., Wesnes K., Hammond G., and Schwalen S. Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease. Curr. Med. Res. Opin. 21 9 (2005) 1423-1429